Université Grenoble Alpes, Inserm, CHU Grenoble Alpes, HP2, U1300, 38000 Grenoble, France.
Institut de Biologie et Chimie des Protéines UMR5305-LBTI, CNRS, Lyon-7, Passage du Vercors, CEDEX 07, 69367 Lyon, France.
Int J Mol Sci. 2022 Nov 3;23(21):13464. doi: 10.3390/ijms232113464.
Elastic fibers, made of elastin (90%) and fibrillin-rich microfibrils (10%), are the key extracellular components, which endow the arteries with elasticity. The alteration of elastic fibers leads to cardiovascular dysfunctions, as observed in elastin haploinsufficiency in mice () or humans (supravalvular aortic stenosis or Williams-Beuren syndrome). In and mice, we evaluated (arteriography, histology, qPCR, Western blots and cell cultures) the beneficial impact of treatment with a synthetic elastic protein (SEP), mimicking several domains of tropoelastin, the precursor of elastin, including hydrophobic elasticity-related domains and binding sites for elastin receptors. In the aorta or cultured aortic smooth muscle cells from these animals, SEP treatment induced a synthesis of elastin and fibrillin-1, a thickening of the aortic elastic lamellae, a decrease in wall stiffness and/or a strong trend toward a reduction in the elastic lamella disruptions in mice. SEP also modified collagen conformation and transcript expressions, enhanced the aorta constrictive response to phenylephrine in several animal groups, and, in female mice, it restored the normal vasodilatory response to acetylcholine. SEP should now be considered as a biomimetic molecule with an interesting potential for future treatments of elastin-deficient patients with altered arterial structure/function.
弹性纤维由弹性蛋白(90%)和富含原纤维蛋白的微纤维(10%)组成,是赋予动脉弹性的关键细胞外成分。弹性纤维的改变会导致心血管功能障碍,如在小鼠弹性蛋白单倍不足()或人类(主动脉瓣上狭窄或威廉姆斯-贝伦综合征)中观察到的那样。在和 小鼠中,我们评估了(血管造影、组织学、qPCR、Western 印迹和细胞培养)用合成弹性蛋白(SEP)治疗的有益影响,该蛋白模拟了弹性蛋白前体原纤维蛋白的几个结构域,包括疏水性弹性相关结构域和弹性蛋白受体的结合位点。在这些动物的主动脉或培养的主动脉平滑肌细胞中,SEP 处理诱导弹性蛋白和原纤维蛋白-1的合成、主动脉弹性层的增厚、壁硬度的降低和/或弹性层破坏的强烈趋势在 小鼠中减少。SEP 还改变了胶原蛋白构象和转录表达,增强了几种动物组中对苯肾上腺素的主动脉收缩反应,并在雌性 小鼠中恢复了对乙酰胆碱的正常血管舒张反应。SEP 现在应被视为一种仿生分子,具有治疗弹性蛋白缺乏的动脉结构/功能改变患者的潜在应用前景。